{"transactions":[{"id":752510,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41900,"kind":"person","name":"Pisano Wayne","position":1,"cik":"0001743611","reported_name":"Pisano Wayne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:46.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027095/ownership.xml","form_type":"4"}},{"id":752509,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41899,"kind":"person","name":"RIGBY JONATHAN","position":1,"cik":"0001356227","reported_name":"RIGBY JONATHAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:44.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027097","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027097/ownership.xml","form_type":"4"}},{"id":752508,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41898,"kind":"person","name":"Holtham Angela","position":1,"cik":"0002102488","reported_name":"Holtham Angela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:38.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027092","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027092/ownership.xml","form_type":"4"}},{"id":752507,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:37.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027089","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027089/ownership.xml","form_type":"4"}},{"id":752506,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41897,"kind":"person","name":"Look Kirk","position":1,"cik":"0002103582","reported_name":"Look Kirk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2026-06-03T20:30:35.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":260000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001493152-26-027091","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027091/ownership.xml","form_type":"4"}},{"id":752505,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2026-06-03T20:30:34.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":260000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001493152-26-027088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027088/ownership.xml","form_type":"4"}},{"id":752504,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41895,"kind":"person","name":"Kelly Jared","position":1,"cik":"0002103581","reported_name":"Kelly Jared","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2026-06-03T20:30:29.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":755000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":755000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":755000},"source":{"system":"sec-edgar","filing":"0001493152-26-027084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027084/ownership.xml","form_type":"4"}},{"id":752503,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41894,"kind":"person","name":"Andrews Patricia S","position":1,"cik":"0001445710","reported_name":"Andrews Patricia S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:26.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027083","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027083/ownership.xml","form_type":"4"}},{"id":752502,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:21.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027081","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027081/ownership.xml","form_type":"4"}},{"id":752501,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41893,"kind":"person","name":"Hagerman Allison","position":1,"cik":"0002103583","reported_name":"Hagerman Allison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option","published_at":"2026-06-03T20:30:19.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":260000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001493152-26-027080","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027080/ownership.xml","form_type":"4"}},{"id":752500,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41892,"kind":"person","name":"Brown Deborah Margaret","position":1,"cik":"0002103580","reported_name":"Brown Deborah Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:16.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027099","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027099/ownership.xml","form_type":"4"}},{"id":752499,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41891,"kind":"person","name":"Heineman Thomas Charles","position":1,"cik":"0002103579","reported_name":"Heineman Thomas Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2026-06-03T20:30:15.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":260000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001493152-26-027078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027078/ownership.xml","form_type":"4"}},{"id":752498,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41890,"kind":"person","name":"McAdory John Bearden","position":1,"cik":"0002137500","reported_name":"McAdory John Bearden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option","published_at":"2026-06-03T20:30:14.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":145000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001493152-26-027101","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027101/ownership.xml","form_type":"4"}},{"id":752497,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:13.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":96000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001493152-26-027100","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027100/ownership.xml","form_type":"4"}},{"id":844372,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-13T12:00:03.000Z","date":"2026-03-11","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.03,"value":10300.0,"ownership":{"direct":true},"balance_after":41849,"source":{"system":"sec-edgar","filing":"0001493152-26-009983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226009983/ownership.xml","form_type":"4"}},{"id":844369,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41895,"kind":"person","name":"Kelly Jared","position":1,"cik":"0002103581","reported_name":"Kelly Jared","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-03-13T12:00:01.000Z","date":"2026-03-12","kind":"purchase","planned":false,"acquired":true,"shares":5050,"price":0.96,"value":4848.0,"ownership":{"direct":true},"balance_after":114050,"source":{"system":"sec-edgar","filing":"0001493152-26-009982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226009982/ownership.xml","form_type":"4"}},{"id":905640,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41895,"kind":"person","name":"Kelly Jared","position":1,"cik":"0002103581","reported_name":"Kelly Jared","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-02-13T12:00:32.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":29500,"price":0.842,"value":24839.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":109000,"source":{"system":"sec-edgar","filing":"0001493152-26-006545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006545/ownership.xml","form_type":"4"}},{"id":905639,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41895,"kind":"person","name":"Kelly Jared","position":1,"cik":"0002103581","reported_name":"Kelly Jared","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-02-13T12:00:32.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":5600,"price":0.836,"value":4681.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":79500,"source":{"system":"sec-edgar","filing":"0001493152-26-006545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006545/ownership.xml","form_type":"4"}},{"id":905638,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41897,"kind":"person","name":"Look Kirk","position":1,"cik":"0002103582","reported_name":"Look Kirk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-02-13T12:00:30.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.842,"value":10104.0,"ownership":{"direct":true},"balance_after":287515,"source":{"system":"sec-edgar","filing":"0001493152-26-006546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006546/ownership.xml","form_type":"4"}},{"id":905637,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41900,"kind":"person","name":"Pisano Wayne","position":1,"cik":"0001743611","reported_name":"Pisano Wayne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-13T12:00:29.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.8446,"value":25338.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.83 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":492414,"source":{"system":"sec-edgar","filing":"0001493152-26-006547","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006547/ownership.xml","form_type":"4"}},{"id":905636,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41891,"kind":"person","name":"Heineman Thomas Charles","position":1,"cik":"0002103579","reported_name":"Heineman Thomas Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-02-13T12:00:28.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":12132,"price":0.827,"value":10033.164,"ownership":{"direct":true},"balance_after":282818,"source":{"system":"sec-edgar","filing":"0001493152-26-006544","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006544/ownership.xml","form_type":"4"}},{"id":905635,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41892,"kind":"person","name":"Brown Deborah Margaret","position":1,"cik":"0002103580","reported_name":"Brown Deborah Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-13T12:00:26.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":0.8496,"value":21240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.835 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":109851,"source":{"system":"sec-edgar","filing":"0001493152-26-006542","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006542/ownership.xml","form_type":"4"}},{"id":905634,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41893,"kind":"person","name":"Hagerman Allison","position":1,"cik":"0002103583","reported_name":"Hagerman Allison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Product Development"}}],"security":"Common Shares","published_at":"2026-02-13T12:00:25.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.8298,"value":8298.0,"ownership":{"direct":true},"balance_after":115059,"source":{"system":"sec-edgar","filing":"0001493152-26-006543","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006543/ownership.xml","form_type":"4"}},{"id":905633,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-13T12:00:23.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0.8466,"value":33864.0,"ownership":{"direct":true},"balance_after":566991,"source":{"system":"sec-edgar","filing":"0001493152-26-006548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006548/ownership.xml","form_type":"4"}},{"id":905632,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-13T12:00:23.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":0.8265,"value":49590.0,"ownership":{"direct":true},"balance_after":526991,"source":{"system":"sec-edgar","filing":"0001493152-26-006548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006548/ownership.xml","form_type":"4"}},{"id":905631,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2026-02-13T12:00:22.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":29600,"price":0.8587,"value":25417.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":55100,"source":{"system":"sec-edgar","filing":"0001493152-26-006541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006541/ownership.xml","form_type":"4"}},{"id":905630,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41894,"kind":"person","name":"Andrews Patricia S","position":1,"cik":"0001445710","reported_name":"Andrews Patricia S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-13T12:00:21.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":35400,"price":0.8557,"value":30291.78,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8483 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":78128,"source":{"system":"sec-edgar","filing":"0001493152-26-006540","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006540/ownership.xml","form_type":"4"}},{"id":935677,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-01-20T21:30:18.000Z","date":"2026-01-16","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.0377,"value":103770.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0294 to $1.0499, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":466991,"source":{"system":"sec-edgar","filing":"0001493152-26-002879","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226002879/ownership.xml","form_type":"4"}}]}